Dosing and Administration
SHINGRIX should be refrigerated. DO NOT FREEZE:
Store both the antigen and adjuvant between
|SHINGRIX is supplied as an adjuvant and antigen for reconstitution: The antigen is to be reconstituted only with the accompanying adjuvant suspension. After reconstitution, SHINGRIX should be administered immediately or stored refrigerated between 2° and 8°C (36° and 46°F) and used within 6 hours. Discard reconstituted vaccine if not used within 6 hours. Do not freeze. Discard if the reconstituted vaccine has been frozen.1
|SHINGRIX is a recombinant vaccine for intramuscular injection only.1
SHINGRIX is administered as a 2-dose series:
The second dose should be administered anytime between 2 and 6 months after the first dose to complete the 2-dose series as directed.1
View reconstitution instructions for SHINGRIX.
†In a phase 3 clinical study designed to help establish the dosing interval for SHINGRIX, all primary endpoints were met for dosing at a 0- and 6-month interval when compared to dosing at a 0- and 2-month interval. However, a co-primary endpoint (noninferiority) of the immune response was missed for dosing at a 0- and 12-month interval. (The upper limit of the 97.5% confidence interval was 1.53, above the predefined limit of <1.5.)4 GSK has not studied the safety or immune response of 3 doses of SHINGRIX in the indicated population (patients ≥50 years of age).1
CDC=Centers for Disease Control and Prevention.
- Prescribing Information for SHINGRIX.
- Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108.
- Centers for Disease Control and Prevention. Frequently Asked Questions About Shingrix. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/faqs.html. Updated August 22, 2018. Accessed September 11, 2018.
- Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148-154.